V. T. K. Le-Trilling

This study identifies pUS28 as a viral protein that inhibits CIITA-driven HLA-II expression, thereby blocking CD4+ T-cell recognition of HCMV-infected cells.

The paper identifies critical antiviral residues in IFN subtypes and designs improved IFN molecules with enhanced antiviral activity against HIV and HBV.

This study investigates how HCMV US10 protein regulates HLA-I genotype and surface expression, revealing its multimodal effects on different HLA-I allotypes.

This study identifies E27 as a viral protein that targets STAT2 for degradation via CRL4 ubiquitin ligases, revealing its structural mechanism of interferon antagonism.

This study shows that acute CMV infection alters gut microbiota and targets intestinal epithelial cells, leading to colitis in immunocompetent hosts.

The paper uses multi-omics data to model HCMV gene regulation, identifying over 2,600 viral transcripts and explaining protein expression kinetics through transcription start sites and RNA stability.

The paper identifies differential antiviral effects of IFN-alpha subtypes against SARS-CoV-2 and highlights IFN5's superior activity, suggesting therapeutic potential.

The study compares antibody responses in asymptomatic and symptomatic SARS-CoV-2感染者, finding that symptomatic individuals maintain higher and longer-lasting IgG and neutralizing capacities.

This paper shows HCMV uses gp34 and gp68 to block FcγR activation by different mechanisms that work together to evade antibody-mediated immunity.

This study shows that HBV vaccines based on modified CMV vectors can clear HBV in mice through enhanced CD8+ T cell responses in both prophylactic and therapeutic settings.